BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
· bullfrog ai holdings, inc.
AI Briefing
- BullFrog AI partners with a top 5 pharmaceutical company to apply its AI platform to identify and prioritize drug targets for major depressive disorder.
- The partnership aims to accelerate the drug discovery and clinical development process for MDD, a market expected to reach $11 billion by 2032.
- The agreement provides exclusive access to a target candidate and expands BullFrog AI's presence in the pharmaceutical industry.
Advertisement